Tag: equity

REGINA, Saskatchewan, June 26, 2026 (GLOBE NEWSWIRE) -- Information Services Corporation (TSX:ISC) (“ISC” or the “Company”) is pleased to announce that, at the special meeting (the “Meeting”) of shareholders held earlier today, ISC shareholders (“Shareholders”) voted in favour of the special resolution (the “Arrangement Resolution”) approving the previously announced plan of arrangement (the “Transaction”) under The Business Corporations Act, 2021 (Saskatchewan) (the “SBCA”), pursuant to which a wholly-owned subsidiary of Plenary Americas LP (“Plenary Americas”) will acquire all of the issued and outstanding Class A Limited Voting Shares (the “Shares”) of ISC at a price per Share of CAD$51.00 (other than those Shares held by certain members of ISC’s senior management who have entered into equity rollover agreements to retain an interest in ISC following closing of the Transaction in respect of the Shares owned by them (the “Rollover Shareholders”)).

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- (TSX: PIC.A; PIC.PR.A) Premium Income Corporation (the “Fund”) announces results of operations for the six months ended April 30, 2026. Increase in net assets attributable to holders of Class A shares amounted to $69.8 million or $3.91 per Class A share. Net assets attributable to holders of Class A shares as at April 30, 2026 were $229.4 million or $12.39 per Class A share ($11.26 per Class A share after giving effect to the May 2026 Share Split). Cash distributions of $0.64 per Preferred share and $0.52 per Class A share were paid during the period.

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.

4,594,880,616 shares traded amounting to $334.027 billion

WALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 65,100 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on June 25, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000^® Index, the large-cap Russell 1000^® Index, the small-to-mid-cap Russell 2500^® Index, and the Russell Midcap^® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.